You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 17, 2025

CLINICAL TRIALS PROFILE FOR MEPIVACAINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for MEPIVACAINE HYDROCHLORIDE

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00825786 ↗ Ultrasound Guided Supraclavicular Nerve Block Completed The Cleveland Clinic Phase 3 2008-09-01 This study will test the hypothesis that sequential injection of 1.5% mepivacaine followed 90 seconds later by 0.5% ropivacaine in ultrasound guided supraclavicular block provides a quicker onset and a longer duration of analgesia than an equi-dose mixture of the two local anesthetics.
NCT00803725 ↗ Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy Completed University Health Network, Toronto N/A 2008-08-01 The purpose of this study is to determine if the addition of intrathecal fentanyl to low dose mepivacaine spinal anesthesia provides adequate surgical anesthesia with shorter duration of motor blockade. It is hypothesized that lower doses of spinal mepivacaine when combined with fentanyl will result in adequate surgical block for knee arthroscopy surgery with faster recovery and discharge compared to mepivacaine alone.
NCT00567450 ↗ Ropivacaine Versus Ropivacaine Plus Mepivacaine for Sciatic Block Completed Centre Hospitalier Universitaire, Amiens Phase 4 2007-09-01 In loco regional anesthesia, much more than for general anesthesia, the choice of the product is largely left at the discretion of the practitioner. Two categories of local anesthetics are distinguished according to their pharmacodynamic characteristics: products with a short time of installation and a short duration period, and products with a longer delay of installation of the sensitive and motor block, but with a long-term duration. Indeed, the combined use of two products pharmacodynamically different seems to be of a practical interest. This study provides a comparison of the onset of action of 30 ml of ropivacaine 0.75% and 30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5% for the subgluteal sciatic nerve block. This is a prospective randomized double-blind study where the main criterion of judgment is the time of installation of a sensitive block compatible with surgery in the sciatic territory nerve. Fifteen patients per group were calculated to detect a 50% decrease of the onset of action in the combination group with a power of 90% and alpha to 5%, according to a previous pilot study. The secondary endpoints are the intensity and time of installation of the motor block, the duration of sensitive and motor block, the total dose of morphine administered within 48 hours, as well as its possible side effects.
NCT00841841 ↗ Dipyrone Versus Acetaminophen in the Control of Postoperative Pain Completed University of Sao Paulo Phase 2 2006-03-01 Adequate postoperative pain management is challenging for practitioners despite recent advances in pain control techniques and analgesic agents. The purpose of this study is to compare the efficacy of Dipyrone and acetaminophen in postoperative pain after third molar surgery.
NCT00841841 ↗ Dipyrone Versus Acetaminophen in the Control of Postoperative Pain Completed University Center of Araraquara Phase 2 2006-03-01 Adequate postoperative pain management is challenging for practitioners despite recent advances in pain control techniques and analgesic agents. The purpose of this study is to compare the efficacy of Dipyrone and acetaminophen in postoperative pain after third molar surgery.
NCT00154167 ↗ Safety and Efficacy Study of NV-101 in Dental Patients Completed Novalar Pharmaceuticals, Inc. Phase 2 2003-02-01 The purpose of this study was: - to determine if NV-101 accelerates recovery from numbness compared to placebo - to evaluate safety of NV-101
NCT00121329 ↗ 4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions Completed Oregon Health and Science University N/A 1969-12-31 Recent studies have investigated the use of local anesthetics (i.e. lidocaine, mepivacaine) to lessen the pain experienced with minor gynecologic procedures such as endometrial biopsy and office hysteroscopy. Local anesthetic injected into the uterine cavity has been demonstrated effective in some studies at decreasing patient pain associated with these intrauterine procedures at an anesthetic concentration of at least 2%. Based on this evidence, we hypothesized that an intrauterine lidocaine infusion may reduce patient pain during first trimester abortions.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 7 of 7 entries

Clinical Trial Conditions for MEPIVACAINE HYDROCHLORIDE

Condition Name

87440012345678Symptomatic Irreversible PulpitisPainAnesthesiaPostoperative Pain[disabled in preview]
Condition Name for MEPIVACAINE HYDROCHLORIDE
Intervention Trials
Symptomatic Irreversible Pulpitis 8
Pain 7
Anesthesia 4
Postoperative Pain 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

14933002468101214PulpitisPain, PostoperativeOsteoarthritis, HipOsteoarthritis[disabled in preview]
Condition MeSH for MEPIVACAINE HYDROCHLORIDE
Intervention Trials
Pulpitis 14
Pain, Postoperative 9
Osteoarthritis, Hip 3
Osteoarthritis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for MEPIVACAINE HYDROCHLORIDE

Trials by Country

+
Trials by Country for MEPIVACAINE HYDROCHLORIDE
Location Trials
United States 23
Egypt 8
Brazil 7
Spain 4
Italy 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for MEPIVACAINE HYDROCHLORIDE
Location Trials
Massachusetts 2
Minnesota 2
North Carolina 2
Tennessee 2
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for MEPIVACAINE HYDROCHLORIDE

Clinical Trial Phase

39.7%9.0%6.4%44.9%05101520253035Phase 4Phase 3Phase 2/Phase 3[disabled in preview]
Clinical Trial Phase for MEPIVACAINE HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 31
Phase 3 7
Phase 2/Phase 3 5
[disabled in preview] 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

64.2%13.6%9.9%12.3%0510152025303540455055CompletedNot yet recruitingUnknown status[disabled in preview]
Clinical Trial Status for MEPIVACAINE HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 52
Not yet recruiting 11
Unknown status 8
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MEPIVACAINE HYDROCHLORIDE

Sponsor Name

trials012345678910111213Cairo UniversityUniversity of Sao PauloHospital for Special Surgery, New York[disabled in preview]
Sponsor Name for MEPIVACAINE HYDROCHLORIDE
Sponsor Trials
Cairo University 12
University of Sao Paulo 4
Hospital for Special Surgery, New York 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

96.2%0-100102030405060708090100110OtherIndustryU.S. Fed[disabled in preview]
Sponsor Type for MEPIVACAINE HYDROCHLORIDE
Sponsor Trials
Other 100
Industry 3
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Mepivacaine Hydrochloride: Clinical Trials, Market Analysis, and Projections

Introduction

Mepivacaine hydrochloride is a local anesthetic widely used in various medical procedures, including dental, surgical, and obstetrical practices. This article will delve into the current clinical trials, market analysis, and future projections for this drug.

Clinical Pharmacology and Usage

Mepivacaine hydrochloride is an amide-type local anesthetic known for its rapid onset and moderate duration of action. It is indicated for the production of local anesthesia by infiltration or nerve block in adults and pediatric patients, particularly in dental procedures[4].

Age-Related Considerations

Studies have shown that the efficacy and dosage of mepivacaine can vary with age. For instance, elderly patients require less mepivacaine to achieve the same level of anesthesia compared to younger adults, due to changes in body composition and pharmacokinetics[1].

Metabolism and Excretion

Mepivacaine is extensively metabolized in the liver through hydroxylation and N-demethylation, with less than 10% of the dose excreted unchanged in the urine. The majority of the metabolized drug is excreted into the bile and then into the urine[2][4].

Current Clinical Trials

While there are no recent clinical trials specifically focused on mepivacaine hydrochloride, the broader context of local anesthetics includes ongoing research and developments.

Market Context

The global local anesthesia drugs market is growing, with a projected CAGR of 3.6% from 2024 to 2030. This growth is driven by advancements in pain management strategies and the introduction of new formulations and delivery methods[3].

Market Analysis

Market Size and Growth

The global local anesthesia drugs market was valued at USD 4.01 billion in 2023. Mepivacaine, although not the fastest-growing segment, remains a significant player due to its established use and safety profile[3].

Competitive Landscape

Mepivacaine competes with other local anesthetics such as lidocaine, articaine, and ropivacaine. Ropivacaine is expected to register the fastest CAGR during the forecast period due to its favorable safety profile and longer duration of action[3].

Niche Market

Mepivacaine has a niche market, particularly among elderly or cardiovascular disease patients, where it is preferred due to its availability without vasoconstrictors or with levonordefrin. This makes it a safer alternative to lidocaine in certain patient populations[5].

Projections and Future Outlook

Market Trends

The increasing demand for multimodal pain management strategies and the development of new injectable treatment options are expected to drive the growth of the local anesthetic market. Mepivacaine, with its established safety and efficacy, is likely to maintain its market share[3].

Environmental Considerations

From an environmental perspective, mepivacaine hydrochloride is predicted to present an insignificant risk. The Predicted Environmental Concentration (PEC) to Predicted No Effect Concentration (PNEC) ratio is very low, indicating minimal environmental impact[2].

Key Takeaways

  • Clinical Usage: Mepivacaine hydrochloride is widely used for local anesthesia in various medical procedures.
  • Metabolism: It is rapidly metabolized in the liver and excreted primarily through the urine.
  • Market Growth: The global local anesthesia drugs market is growing, with mepivacaine maintaining a significant market share.
  • Niche Market: It is preferred in certain patient populations due to its safety profile.
  • Environmental Impact: Mepivacaine hydrochloride has an insignificant environmental risk.

FAQs

What is mepivacaine hydrochloride used for?

Mepivacaine hydrochloride is used for the production of local anesthesia by infiltration or nerve block in adults and pediatric patients, particularly in dental procedures.

How does mepivacaine hydrochloride compare to other local anesthetics?

Mepivacaine has a lower anesthetic potency compared to lidocaine and prilocaine but is preferred in certain patient populations due to its safety profile and availability with or without vasoconstrictors.

What is the metabolic pathway of mepivacaine hydrochloride?

Mepivacaine is extensively metabolized in the liver through hydroxylation and N-demethylation, with less than 10% of the dose excreted unchanged in the urine.

What is the projected growth of the local anesthesia drugs market?

The global local anesthesia drugs market is projected to grow at a CAGR of 3.6% from 2024 to 2030.

Does mepivacaine hydrochloride pose any environmental risk?

Mepivacaine hydrochloride is predicted to present an insignificant environmental risk based on the PEC/PNEC ratio.

Sources

  1. CARBOCAINE Clinical Pharmacology - Pfizer Medical Information
  2. Environmental Risk Assessment Data Mepivacaine hydrochloride - AstraZeneca
  3. Local Anesthesia Drugs Market Size & Share Report, 2030 - Grand View Research
  4. Mepivacaine: Package Insert / Prescribing Information - Drugs.com
  5. Mepivacaine: a closer look at its properties and current utility - AGD

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.